Education
About Us
Working with TipRanks
Follow Us
Pyxis Oncology (PYXS)
NASDAQ:PYXS
PYXS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.83 - $5.39
Previous CloseN/A
Volume258.73K
Average Volume (3M)595.60K
Market Cap
$66.90M
Enterprise Value-$116.11M
Total Cash (Recent Filing)$105.43M
Total Debt (Recent Filing)$19.84M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Aug 19, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding61,947,666
10 Day Avg. Volume1,028,660
30 Day Avg. Volume595,597
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.28
Price to Sales (P/S)0.00
P/FCF Ratio-0.46
Enterprise Value/Market Cap-1.74
Enterprise Value/Revenue-1.87
Enterprise Value/Gross Profit-104.04
Enterprise Value/Ebitda0.41
Forecast
1Y Price Target
$6.67Price Target Upside455.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Pyxis Oncology News
PremiumCompany Announcements
Pyxis Oncology Appoints New Principal Financial Officer
PremiumCompany Announcements
Pyxis Oncology Elects New Directors at Annual Meeting
PremiumCompany Announcements
Pyxis Oncology Reports Increased Losses Amidst Ongoing R&D Investments
PremiumCompany Announcements
Pyxis Oncology Reports Q1 Loss and Business Update
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentMICVO showed the strongest activity in head and neck cancer, validating Pyxis’ development focus.
Financial StabilityManagement believes current cash is sufficient to fund operations into 2H26.
Strategic ManagementThe assumption of CMO duties by CEO Lara Sullivan is seen as a strategic move to enhance focus and efficiency in clinical execution.
Bears Say
Clinical EfficacyDespite the attractive setup, follow-up will likely be too immature to assess durability.
Financial PerformanceNet loss of $21.2 million, or a loss of $0.35 per share, was comparable to the projected loss, indicating financial challenges.
Investor SentimentPYXS’s persistent underperformance and negative EV evidently reflects continued investor skepticism of micvo’s opportunity in SCCHN.
Ownership Overview
10.31% Insiders
6.06% Mutual Funds
25.01% Other Institutional Investors
51.18% Public Companies and Individual Investors
PYXS FAQ
What was Pyxis Oncology’s price range in the past 12 months?
Pyxis Oncology lowest stock price was $0.83 and its highest was $5.39 in the past 12 months.
What is Pyxis Oncology’s market cap?
Pyxis Oncology’s market cap is $66.90M.
When is Pyxis Oncology’s upcoming earnings report date?
Pyxis Oncology’s upcoming earnings report date is Aug 19, 2025 which is in 47 days.
How were Pyxis Oncology’s earnings last quarter?
Pyxis Oncology released its earnings results on May 15, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.294 by -$0.056.
Is Pyxis Oncology overvalued?
According to Wall Street analysts Pyxis Oncology’s price is currently Undervalued.
Does Pyxis Oncology pay dividends?
Pyxis Oncology does not currently pay dividends.
What is Pyxis Oncology’s EPS estimate?
Pyxis Oncology’s EPS estimate is -0.35.
How many shares outstanding does Pyxis Oncology have?
Pyxis Oncology has 61,947,666 shares outstanding.
What happened to Pyxis Oncology’s price movement after its last earnings report?
Pyxis Oncology reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.294. Following the earnings report the stock price went up 3.738%.
Which hedge fund is a major shareholder of Pyxis Oncology?
Currently, no hedge funds are holding shares in PYXS
Pyxis Oncology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.67 (455.83% Upside)
$6.67 (455.83% Upside)
Blogger Sentiment
Bullish
PYXS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 218.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.25%
12-Months-Change
Fundamentals
Return on Equity
-66.30%
Trailing 12-Months
Asset Growth
-38.30%
Trailing 12-Months
Company Description
Pyxis Oncology
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
PYXS Stock 12 Month Forecast
Average Price Target
$6.67
▲(455.83%Upside)
Technical Analysis
Avalo Therapeutics
―
Renovaro Biosciences
―
Cabaletta Bio
―
Alto Neuroscience, Inc.
―
Metagenomi, Inc.
―